Acumen Pharmaceuticals (ABOS) Non-Current Debt (2023 - 2026)
Acumen Pharmaceuticals (ABOS) posted Non-Current Debt of $16.9 million for Q1 2026, down 24.43% sequentially from $22.4 million in Q4 2025, and down 42.68% YoY from $29.5 million in Q1 2025.
Acumen Pharmaceuticals (ABOS) Non-Current Debt (2023 - 2026) Analysis & Trends
Acumen Pharmaceuticals has reported Non-Current Debt for 4 years, with the latest figure at $16.9 million in Q1 2026.
- Quarterly Non-Current Debt fell 42.68% year-over-year to $16.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.9 million (down 42.68% YoY) and the FY2025 annual result came in at $22.4 million, down 23.87% from the prior year.
- Non-Current Debt eased to $16.9 million in Q1 2026 per ABOS's latest filing, from $22.4 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $30.2 million in Q1 2024 and troughed at $16.9 million in Q1 2026.
- A 4-year average of $27.4 million and a median of $29.5 million in 2024 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2025 and 2026: Non-Current Debt gained 1.71% in 2025, then tumbled 42.68% in 2026.
- Over 4 years, Non-Current Debt stood at $29.9 million in 2023, then retreated by 1.6% to $29.4 million in 2024, then slipped by 23.87% to $22.4 million in 2025, then decreased by 24.43% to $16.9 million in 2026.
- According to Business Quant data, Non-Current Debt over the past three periods registered $16.9 million, $22.4 million, and $27.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.49 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.24 Bn | 78.25 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.83 Bn | 53.69 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.44 Bn | - | 8.96 Bn |
| 10 | Acumen Pharmaceuticals | 231.20 Mn | 231.20 Mn | - | 11.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.90 Mn |
| Mar 31, 2026 | 16.92 Mn |
| Dec 31, 2025 | 22.40 Mn |
| Sep 30, 2025 | 27.05 Mn |
| Jun 30, 2025 | 29.88 Mn |
| Mar 31, 2025 | 29.53 Mn |
| Dec 31, 2024 | 29.42 Mn |
| Sep 30, 2024 | 29.67 Mn |
| Jun 30, 2024 | 29.38 Mn |
| Mar 31, 2024 | 30.21 Mn |
| Dec 31, 2023 | 29.90 Mn |